Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
Summary
The USPTO granted Patent US12589140B2 to The Brigham and Women's Hospital, Inc. covering methods for generating immune responses to cancer or infection by promoting differentiation of neutrophils into dendritic cells using GMCSF combined with immune complexes or anti-FcγRIIIB antibodies. The patent contains 14 claims and lists Tanya Mayadas, Vijaya Mysore, Xavier Cullere, and Jon C. Aster as inventors.
What changed
The USPTO issued Patent No. US12589140B2 titled 'Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof' to The Brigham and Women's Hospital, Inc. The patent claims methods for generating immune responses by differentiating neutrophils into dendritic cells using GMCSF plus either immune complexes containing Fc region-binding antibodies, antigen-anti-FcγRIIIB antibody conjugates, or anti-FcγRIIIB antibodies alone. The technology has applications in cancer and infectious disease treatment.
This patent grant establishes enforceable intellectual property rights that may impact researchers, pharmaceutical companies, and biotech firms working on neutrophil-based immunotherapies. Parties developing related immune therapy products should evaluate potential licensing needs or design-around considerations to avoid infringement. The patent application was filed on January 22, 2020, under Application No. 17424431.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
Grant US12589140B2 Kind: B2 Mar 31, 2026
Assignee
The Brigham and Women's Hospital, Inc.
Inventors
Tanya Mayadas, Vijaya Mysore, Xavier Cullere, Jon C. Aster
Abstract
Methods and compositions for use in generating or promoting an immune response to cancer or an infection, comprising promoting differentiation of neutrophils into dendritic cells using a combination of GMCSF and (i) an immune complex comprising an antigen and an antibody comprising an Fc region that binds to FcγRIIA or FcγRIIIB, (ii) a conjugate comprising an antigen and an anti-FcγRIIIB antibody, or (iii) an anti-FcγRIIIB antibody.
CPC Classifications
A61K 38/193 A61K 39/0005 A61K 39/4615 A61K 39/4622 A61K 39/464401 A61K 39/464411 A61K 39/39 A61K 47/6849 A61K 2039/505 A61K 2039/572 A61P 35/00 C07K 16/283 C07K 2317/75 C12N 5/0639 C12N 2501/22 C12N 2501/998 C12N 2506/11
Filing Date
2020-01-22
Application No.
17424431
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.